Search results
Results from the WOW.Com Content Network
Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep worldwide. It has been approved by the U.S. Food and Drug Administration (FDA) for once daily treatment and prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Cangrelor, sold under the brand name Kengreal among others, is a P2Y 12 inhibitor FDA approved as of June 2015 as an antiplatelet drug [5] for intravenous application. Some P2Y 12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. [5]
Tinzaparin sodium This page was last edited on 7 February 2020, at 01:25 (UTC). Text is available under the Creative Commons Attribution-ShareAlike 4.0 ...
Kips Bay Medical Announces FDA Approval of Additional US Study Patients MINNEAPOLIS--(BUSINESS WIRE)-- Kips Bay Medical, Inc. (NAS: KIPS) along with Manny Villafaña, its Founder, Chairman and CEO ...
Repros Therapeutics Inc. (NASDAQ: RPRX) is surging on clinical update news this Thursday. The company's Androxal Phase 3 program has been given a receipt of written guidance from the Food & Drug ...
In the study, ONP-002 was tested using a nasal spray device. The goal of intranasal casting studies is to identify where the drug lands inside a cast metal anatomical model of the interior nose.
A cerebroprotectant (formerly known as a neuroprotectant) is a drug that is intended to protect the brain after the onset of acute ischemic stroke. [1] As stroke is the second largest cause of death worldwide and a leading cause of adult disability, over 150 drugs have been tested in clinical trials to provide cerebroprotection.
The FDA has asked for a repeat-dose study of the treatment versus a rival i ... The rejection and request for additional testing sharply contrasts the backing from the U.S. Food and Drug ...